{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercalcaemia/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"048198e1-607a-55c4-9d7d-a63135379c28","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 2a96e80a-8a95-4401-b97b-e723d5685ad5 --><h2>How common is it?</h2><!-- end field 2a96e80a-8a95-4401-b97b-e723d5685ad5 -->","summary":"","htmlStringContent":"<!-- begin item e4ecf14f-2136-4e1f-adc2-61e9922419dd --><!-- begin field 7bdc43a7-b757-44cf-bc80-0748c1642412 --><p><strong>Hypercalcaemia is a common disorder, and its prevalence varies depending on the study definitions used, population studied, and the underlying cause </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Jick, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>]<strong>.</strong></p><ul><li>A review article notes that the prevalence of hypercalcaemia in the general population is approximately 1 in 1000 people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].</li><li>Primary hyperparathyroidism is the most common cause of hypercalcaemia, with an estimated prevalence of about 1–7 cases per 1000 adults, and annual incidence ranging from about 4–11 cases per 10,000 person-years in a population-based Scottish study [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Yu et al, 2009</a>].<ul><li>It is more common in older adults with prevalence increasing with age, and it is 2–3 times more common in women than men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Yu et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>].</li><li>Parathyroid cancer as a cause of primary hyperparathyroidism is very rare, with an incidence of about 4 per 10 million person-years in a US population-based study [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Lee, 2007</a>].</li><li>A review article notes that multiple endocrine neoplasia (MEN) syndromes occur in about 1 in 30,000 people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>].</li></ul></li><li>The prevalence of malignancy-associated hypercalcaemia varies in the literature.<ul><li>A UK population-based analysis of a primary care database of adults with malignancy (n = 37,442) found the overall annual prevalence of hypercalcaemia was 0.67%. Prevalence estimates varied with cancer type and stage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Jick, 2015</a>].</li><li>Expert opinion in a review article advises that up to 20% of people with malignancy will be affected by hypercalcaemia at some point in the course of their illness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].</li><li>A review article states that malignancy-associated hypercalcaemia occurs in about 10% of people with advanced cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>]. An additional review article states that the prevalence is 20–30% in people with advanced cancer, with a yearly incidence of 1–2% across all cancer types [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li></ul></li><li>A US population-based study found the annual incidence of thiazide-associated hypercalcaemia was 20 per 100,000, and this occurred an average of 5.2 years after starting treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Griebeler, 2016</a>].</li><li>The prevalence of hypercalcaemia in people taking long-term lithium is reported to be 10–60% in cross-sectional studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Jones and Twomey, 2009</a>].</li><li>Calcium-alkali syndrome is becoming more common due to increased prescribing of calcium and vitamin D preparations in the management of osteoporosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Yoshizawa, 2012</a>].</li><li>Hypercalcaemia occurs in:<ul><li>2–10% of people with sarcoidosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Hunninghake, 1999</a>].</li><li>About 15% of people (n = 94) with active pulmonary tuberculosis in a hospital-based study in India [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Sharma, 1981</a>].</li><li>About 5–10% of people with thyrotoxicosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Chan et al, 1997</a>].</li></ul></li></ul><!-- end field 7bdc43a7-b757-44cf-bc80-0748c1642412 --><!-- end item e4ecf14f-2136-4e1f-adc2-61e9922419dd -->","topic":{"id":"c0ab4dd9-cccf-54af-a952-765aa048de1d","topicId":"897bf773-43ef-4092-a798-d9eb4cbcb9cc","topicName":"Hypercalcaemia","slug":"hypercalcaemia","lastRevised":"Last revised in August 2019","chapters":[{"id":"dfffab44-62c8-5590-8bad-e41f249a89e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"fbfb541d-eae2-5916-af42-b77d9c9ab401","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3c7aba33-da1a-580a-b896-fb6026eb2ad8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d715de-b85d-534b-8c6f-0cf5f59814c2","slug":"changes","fullItemName":"Changes"},{"id":"48c69505-e62a-5332-a3ad-fd44bb64bd34","slug":"update","fullItemName":"Update"}]},{"id":"0105d032-866a-57c0-8c83-2f54f2b7b491","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"989b5402-77d7-5cd9-86a7-979019eba917","slug":"goals","fullItemName":"Goals"},{"id":"5d8d7c84-01cb-59e9-a02e-489cb32e799e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e7c39bf4-b50f-51f7-ad27-49c431acf456","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb69f34-e184-554d-a518-e9d59c4f95de","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d7060151-5501-51fc-b393-844af2c2ca54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7d4d8cad-82f7-5bb5-8c59-b47873b845b2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4408b725-f01f-596c-b319-5ef7dd246c3c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28f41cc2-0513-5841-9fa6-1a59bb557452","slug":"definition","fullItemName":"Definition"},{"id":"b1dd3a7e-6be5-523b-a2c5-c41f9b364798","slug":"causes","fullItemName":"Causes"},{"id":"048198e1-607a-55c4-9d7d-a63135379c28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3c5e2134-d0b1-5804-bc33-86db97dfc33b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"62c64451-7e13-5be6-b868-01f8198a13ac","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dc0291c2-c628-503e-a7f7-7f3fa1362b62","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c5771a8e-2f1e-53ad-a2fc-322152fc3a3e","slug":"confirmation","fullItemName":"Confirmation"},{"id":"44ef7f17-c907-5252-8027-300e87635dc4","slug":"assessment","fullItemName":"Assessment"}]},{"id":"d005c3ba-c691-53c3-b23c-1c70928fb05d","fullItemName":"Management","slug":"management","subChapters":[{"id":"c604ea66-1be5-51cc-b014-9af770bbc709","slug":"unconfirmed-cause","fullItemName":"Scenario: Unconfirmed cause"},{"id":"4863d234-7059-57aa-b9cc-a51e3a1f3424","slug":"known-malignancy","fullItemName":"Scenario: Known malignancy"},{"id":"fb65182a-1069-5bbd-9c43-a547a8632cec","slug":"follow-up-in-primary-care","fullItemName":"Scenario: Follow-up in primary care"}]},{"id":"4017390d-3b38-5741-8d16-22624da35f3d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2ec3d6b5-1818-5b5f-af66-bd097d709bf2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"847bb207-2cb8-5e5f-b3e8-ee87440a71cd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"47a9d106-98da-5683-9641-88d123a8d071","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a8225b5a-40b4-53e5-9095-0953daa376fa","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c60f947f-6176-53b3-9484-54b966632a77","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b6a6af13-45f8-5258-a611-6d8306bbe251","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f68489fb-5d5f-5342-94a0-3979f632012b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4408b725-f01f-596c-b319-5ef7dd246c3c","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}